Departments of Pharmacy.
Department of Palliative Care.
Jpn J Clin Oncol. 2018 Aug 1;48(8):748-752. doi: 10.1093/jjco/hyy079.
Dyspnea is among symptoms that decrease quality of life for terminal cancer patients. There are few reports of the positive effects of oxycodone for the treatment of dyspnea, and no studies have focused on opioid-naïve patients. This study aimed to determine the efficacy and safety of continuous intravenous oxycodone infusion for opioid-naïve cancer patients with dyspnea.
Eligible patients were opioid-naïve cancer inpatients who received continuous oxycodone infusion as a treatment for dyspnea under the care of the palliative care team at Komaki City Hospital between November 2013 and December 2016. We retrospectively investigated the improvement of dyspnea following continuous oxycodone infusion from the medical records.
This study included 19 patients, and the response rate to oxycodone infusion for dyspnea was 68.4%. Most participants were terminal cancer patients with performance status 3 or 4. Median survival of participants following continuous oxycodone infusion was 6 (range 1-377) days. No serious adverse events such as respiratory depression or somnolence were noted.
Continuous oxycodone infusion could be a reasonable treatment option in the management of dyspnea in opioid-naïve cancer patients.
呼吸困难是晚期癌症患者生活质量下降的症状之一。有很少的报告表明羟考酮对呼吸困难有积极的治疗作用，而且没有研究集中在阿片类药物初治患者上。本研究旨在确定持续静脉输注羟考酮对伴有呼吸困难的阿片类药物初治癌症患者的疗效和安全性。
合格的患者是阿片类药物初治的癌症住院患者，在 2013 年 11 月至 2016 年 12 月期间，在癌痛缓和治疗团队的护理下，接受持续羟考酮输注治疗呼吸困难。我们从病历中回顾性调查了持续羟考酮输注对呼吸困难的改善情况。
本研究包括 19 例患者，对羟考酮输注治疗呼吸困难的反应率为 68.4%。大多数参与者是终末期癌症患者，表现状态为 3 或 4 级。参与者在接受持续羟考酮输注后的中位生存时间为 6（范围 1-377）天。没有出现严重的不良反应，如呼吸抑制或嗜睡。
持续输注羟考酮可能是阿片类药物初治癌症患者呼吸困难管理的一种合理治疗选择。
